Updated September 2026Branded and compounded priced togetherMaximus review
Compounded semaglutide and the branded product are listed at the same monthly figure on this seller's plans.
The verdict
Maximus prices compounded semaglutide and branded semaglutide identically at $249.99 a month on a one-month plan. On tirzepatide the two diverge, at $359.99 compounded against $449.99 for the branded pen.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- sellers of the branded GLP-1 products
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- Dose pricing
- Flat across doses
- States
- 51
- From
- $249.99/mo
- Prescription
- Required
Maximus sells both compounded preparations and the manufacturers' finished products, on plans of one, four and twelve months. The one-month plan carried $249.99 for semaglutide and $359.99 for compounded tirzepatide on August 16, 2026. Branded tirzepatide on the same plan was $449.99, dispensed as a multi-dose pen at the same self-pay rate as the vial. Coverage extends to all fifty states and the District of Columbia.
Who writes the prescription, and what do they see?
Treatment is arranged online and the plan a reader buys sets the rate. The branded rows are dispensed as the manufacturer's finished product, which requires a prescription written against the approved label. The compounded rows require one as well, written for a preparation the label does not cover. What the intake asks before either is issued is not published.
Treatment is arranged online and the plan term sets the rate rather than the dose. Maximus states a flat rate across doses, so an escalation does not move the monthly figure. The longer plans cut it substantially: compounded semaglutide falls to $199.49 on four months and $150.32 on twelve. Compounded tirzepatide follows the same shape, at $298.99 and $240.66.
What happens when the dose goes up?
Maximus states a flat rate across doses, so the escalation does not move the monthly figure. What moves it is the plan length chosen at the start. A twelve-month plan is bought before the first dose step, and a one-month plan keeps that decision open at $249.99. Whether the branded rows carry the same flat-rate treatment is not published.
What the price includes
The semaglutide decision here costs nothing either way, because both routes are $249.99 on a one-month plan. That is unusual, and it removes price from a choice that normally turns on it. On tirzepatide the branded pen costs $90 a month more than the compounded preparation. Whether the longer plans apply to the branded rows as well as the compounded ones is not recorded here.
What it claims, and what it cites
The branded rows are the manufacturer's own product, reviewed and approved as a finished medicine. The compounded rows are prepared by a pharmacy and are not FDA-approved. That distinction is the one a reader is buying when the two cost the same. Trial results for these molecules were generated with the approved products at label doses, and compounded preparations were not what was studied.
Where it holds up, and where it does not
- Strength: Branded and compounded on one plan page
- Strength: Semaglutide priced the same by either route
- Strength: Rate stated as flat across doses
- Limitation: One-month rate is high for this category
- Limitation: Branded tirzepatide costs $90 more monthly
- Limitation: Best rates need a twelve-month plan
What the evidence says about this kind of treatment
The assessment above is about Maximus. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader weighing a compounded preparation against the manufacturer's own product, where on semaglutide the choice costs nothing either way.
- Wrong for
- A reader shopping the compounded market on price alone, since the one-month rate here sits well above what compounded-only sellers charge.
How Maximus compares
| Seller | Who it suits | Go |
|---|---|---|
| Alloy | A reader comparing three molecules at one seller, where the same fixed fee sits on top of each of them. | See Alloy → |
 Trimi Health | A reader who can pay a year at once, or finance it, and wants the per-month figure to stop moving as the dose rises. | See Trimi Health → |
 Embody | A reader willing to read the terms of service before the checkout total, because the low rate and the listed rate are different numbers. | See Embody → |
More GLP-1 telehealth sellers reviews: Bayan HealthBioGlow HealthCollectiveDoctorAdamEnhance MDEverSlim
Sponsored alternative
Synergy Rx
A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.
Check Synergy Rx availability →Frequently asked
- Is the branded product really the same price as the compounded one?
- On semaglutide, yes: both were $249.99 a month on the one-month plan at the price checked here. On tirzepatide the branded pen was $449.99 against $359.99 for the compounded preparation.
- How much do the longer plans save?
- Compounded semaglutide drops from $249.99 to $199.49 on a four-month plan and $150.32 on twelve months. Compounded tirzepatide drops to $298.99 and $240.66 on the same terms.
- Does the price rise with the dose?
- Maximus states a flat rate across doses. An escalation therefore does not change the monthly figure, which is the point at which many sellers in this category reprice.
- Is Maximus expensive compared with other GLP-1 telehealth sellers?
- Maximus publishes a starting figure of $249.99/mo. Across the 32 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $299 with a median of $139, which puts Maximus above the median. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.